MPC-AEMA Copolymer for Medical Device Surface Biocompatibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for imparting biocompatibility to medical devices face challenges with cytotoxicity and protein adsorption due to the use of toxic monomers and unreacted cationic groups, which affect the durability and safety of medical devices in contact with living tissues.
Innovation Solution
A polymer with phosphorylcholine-like groups reacted with 2-aminoethanethiol is developed, offering improved hydrophilicity and biocompatibility with low cytotoxicity, and a surface treatment agent is created using this polymer for medical devices, ensuring compatibility with body fluids and blood-contacting surfaces.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If a copolymer of MPC and AEMA is used to increase amino groups on medical device surfaces, then durability is improved, but unreacted cationic groups cause protein adsorption and immune cell activation, deteriorating biocompatibility
Solution Approach 1:
The patent introduces a phosphorylcholine group as an intermediary substance that mediates between the amino groups and the biological environment. The phosphorylcholine group maintains the cationic property for surface bonding while its specific structure prevents protein adsorption and immune cell activation, thus resolving the contradiction between durability and biocompatibility
Solution Approach 2:
The patent changes the chemical parameters of the surface coating by incorporating phosphorylcholine groups with specific structural characteristics. This parameter change transforms the surface properties to achieve both high durability through amino group bonding and low biocompatibility issues through the unique structure of phosphorylcholine that resists protein adsorption
2Object-affected harmful factors
If the compositional ratio of AAM in the copolymer is increased to improve biocompatibility, then surface properties are enhanced, but AAM is highly toxic and inconvenient in handling
Solution Approach 1:
The patent replaces the toxic AAM monomer with MPC and AEMA monomers that are safer to handle. The resulting copolymer achieves the desired biocompatibility without requiring high concentrations of toxic AAM, effectively substituting a harmful substance with safer alternatives that achieve the same functional outcome
Solution Approach 2:
The patent uses phosphorylcholine-containing monomers as intermediaries to achieve biocompatibility without relying on toxic AAM. The phosphorylcholine group serves as a safe alternative that provides the necessary biocompatible surface properties without the cytotoxicity associated with high AAM content
3Ease of operation
If conventional coating techniques are used to impart lubricity to medical device surfaces, then surface properties are improved, but the methods do not provide sufficient biocompatibility and durability
Solution Approach 1:
The patent creates a composite surface coating that combines multiple functional groups: amino groups for durable surface bonding, phosphorylcholine groups for biocompatibility and protein adsorption resistance, and lubricious components for ease of operation. This composite structure achieves all three requirements simultaneously that conventional single-function coatings cannot provide
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer effectively imparts hydrophilicity and biocompatibility to medical devices with low cytotoxicity, enhancing their durability and safety by reducing protein adsorption, making them suitable for use in devices like guidewires, catheters, and contact lenses.
Implementation Method 1
The polymer effectively imparts hydrophilicity and biocompatibility to medical devices with low cytotoxicity
Implementation Method 2
capable of imparting surface hydrophilicity and biocompatibility to medical device surfaces by simple processing, and having low cytotoxicity
Data Source
Figure 1~2
AI summary
Provided are a polymer having low cytotoxicity and capable of imparting surface hydrophilicity and biocompatibility to medical device surfaces by simple processing, a method for producing the polymer, and a surface treatment agent for medical devices. The polymer of the present invention has a particular ratio of structural units represented by the formulae (1a) and (1b), and a particular weight average molecular weight, and is useful as a surface treatment agent for various medical devices.